Evidence map›Paper›PMID 30829100›Full record

Trial reportHuman vaccines & immunotherapeutics2019

Cell-mediated immune responses to different formulations of a live-attenuated tetravalent dengue vaccine candidate in subjects living in dengue endemic and non-endemic regions.

Philippe Moris, Kristen M Bauer, Jeffrey R Currier, Heather Friberg, Kenneth H Eckels, Ines O Esquilin, Robert V Gibbons, Bruce L Innis, Richard G Jarman, Sriluck Simasathien and 3 more

3 registry-linked trialsAbstract readClinical Trial, Phase IIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Human vaccines & immunotherapeutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00350337 phase2completednot on this map

Phase II, Randomized, Observer-Blind, Single Center, Controlled Study of Two Doses of Various Formulations of WRAIR Live Attenuated Tetravalent Dengue Vaccine Compared to Placebo Control Administered on 0-6-Month Schedule to Healthy Adults

TypeinterventionalSponsorU.S. Army Medical Research and Development CommandRan2006 to 2008Enrolled86ConditionsDengueArmsPre-transfection F17, Post-transfection F17, Post-transfection F19, Placebo
NCT00370682 phase2completednot on this map

Phase II, Randomized, Double-blind, Single Center, Controlled Study of Two Doses of Different Formulations of the WRAIR Live Attenuated Tetravalent Dengue Vaccine Compared to a Placebo Control, Administered on a 0-6 Month Schedule, to Healthy Adults

TypeinterventionalSponsorU.S. Army Medical Research and Development CommandRan2007 to 2008Enrolled120ConditionsDengueArmsT-DEN F17, T-DEN F-19, Placebo Comparator
NCT00468858 phase2completednot on this map

Phase II, Randomized, Double-blind, Placebo-controlled Study of Two Doses of WRAIR Live Attenuated Tetravalent Dengue Vaccine Formulations, Administered Six Months Apart, to Healthy Adults and Children

TypeinterventionalSponsorU.S. Army Medical Research and Development CommandRan2007 to 2010Enrolled636ConditionsDengue Fever, Dengue Hemorrhagic Fever, Dengue Shock SyndromeArmsPlacebo, T-DEN-Post-Transfection F17, T-DEN-Post-Transfection F19
3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. T Cell Responses During Dengue Infection.Current topics in microbiology and immunology · 2026
    Review
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Philippe MorisGSK , Rixensart , Belgium.
Kristen M BauerLandstuhl Regional Medical Center , Landstuhl , Germany.
Jeffrey R CurrierViral Diseases Branch, Walter Reed Army Institute of Research , Silver Spring , MD , USA.
Heather FribergViral Diseases Branch, Walter Reed Army Institute of Research , Silver Spring , MD , USA.
Kenneth H EckelsPilot Bioproduction Facility, Walter Reed Army Institute of Research , Silver Spring , MD , USA.ORCID 0000-0003-0517-0554
Ines O EsquilinDepartment of Pediatrics, University of Puerto Rico School of Medicine , San Juan , Puerto Rico.
Robert V GibbonsBattlefield Pain Management Task Area, U.S. Army Institute for Surgical Research , Fort Sam Houston , TX , USA.
Bruce L InnisGSK , King of Prussia , PA , USA.
Richard G JarmanViral Diseases Branch, Walter Reed Army Institute of Research , Silver Spring , MD , USA.
Sriluck SimasathienDepartment of Pediatrics, Phramongkutklao Hospital , Bangkok , Thailand.
Peifang SunHenry Jackson Foundation for the Advancement of Military Medicine , Bethesda , MD , USA.
Stephen J ThomasViral Diseases Branch, Walter Reed Army Institute of Research , Silver Spring , MD , USA.
Veerachai WatanaveeradejDepartment of Pediatrics, Phramongkutklao Hospital , Bangkok , Thailand.ORCID 0000-0001-5812-3685

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Three phase II randomized trials evaluated the safety/immunogenicity of two formulations of live-attenuated tetravalent dengue virus (TDEN) vaccine in dengue-endemic (Puerto Rico, Thailand) and non-endemic (US) regions (NCT00350337/NCT00370682/NCT00468858). We describe cell-mediated immune (CMI) responses; safety and humoral responses were reported previously. Participants received two doses of vaccine or control (placebo or the precursor live-attenuated TDEN vaccine) 6 months apart. Selected US participants received a booster 5-12 months post-dose 2. Evaluated subsets of the per-protocol cohorts included 75 primarily dengue virus (DENV)-unprimed US adults, 69 primarily flavivirus-primed Thai adults, and 100 DENV-primed or DENV-unprimed Puerto Rican adults/adolescents/children. T-cell responses were quantified using intracellular cytokine staining (ICS; DENV-infected cell-lysate or DENV-1/DENV-2 peptide-pool stimulation) or IFN-γ ELISPOT (DENV-2 peptide-pool stimulation). Memory B-cell responses were quantified using B-cell ELISPOT. Across populations and age strata, DENV serotype-specific CD4

Indexed as

Immunity, CellularAdolescentAdultAntibodies, ViralChildChild, PreschoolCohort StudiesDengueDengue VaccinesDengue VirusEndemic DiseasesFemaleHumansImmunologic MemoryInfantMaleAntibodies, ViralDengue VaccinesVaccines, AttenuatedCellular-mediated immune responsesDengue-primed and -unprimed populationsLive-attenuated tetravalent dengue candidate vaccine

Identifiers

PMID30829100
PMCPMC6773406

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.